Table 1.
Novel agents in mCRPC treatment, their associated overall survival benefits, and common side effects
| Treatment | Overall survival (OS) benefit | Common side effects (Grade 3–4) |
|---|---|---|
| Enzalutamide (Xtandi®, Astellas) | Fatigue, back pain, arthralgia, and hypertension15 | |
| Pre-docetaxel | 4.0 months compared with placebo15 | |
| Post-docetaxel | 4.8 months compared with placebo16 | |
| Abiraterone acetate plus prednisone (Zytiga®, Janssen) | Anaemia, liver function test abnormalities, hypokalemia, and fluid retention17 | |
| Pre-docetaxel | 4.4 months compared with placebo17 | |
| Post-docetaxel | 4.6 months compared with placebo18 | |
| Docetaxel (Taxotere®, Sanofi) | 2.4–3.0 months compared with mitoxantrone1,19 | Neutropenia, anemia, thrombocytopenia, and fatigue |
| Cabazitaxel (Jevtana®, Sanofi) | 2.4 months compared with mitoxantrone20 | Neutropenia, anemia, thrombocytopenia, and fatigue |
| Radium-223 (Xofigo®, Bayer) | 3.6 months compared with placebo11 | Anemia, neutropenia thrombocytopenia, and bone pain |
mCRPC: metastatic castrate-resistant prostate cancer.